Otago Innovation Ltd — University of Otago's Research Commercialisation Company

Otago Innovation Limited (OIL) is a wholly-owned subsidiary of the University of Otago in Dunedin, New Zealand, established in the early 2000s (commonly dated to 2003, with roots from 2001) with exclusive responsibility for commercialising intellectual property arising from University research, via licensing, spin-out formation and proof-of-concept investment.
The company's record has been uneven. A July 2009 Otago Daily Times investigation found Otago Innovation had been expected to return about NZ$1 million to the University from royalties and IP sales but instead returned only NZ$100,000, with company revenue falling from NZ$1.2 million (2006) to NZ$1.1 million (2007) and a budgeted 2009 surplus of NZ$258,000 revised to a NZ$745,000 loss a month later. University leadership at the time declined to explain the shortfall publicly.
More recently, in July 2021 Otago Innovation co-led what it described as its largest-ever investment: a NZ$14 million raise for Amaroq Therapeutics, a University of Otago spin-out developing lncRNA-targeted cancer therapeutics, alongside life-science investor Brandon Capital, NZ Innovation Booster and Cure Kids Ventures. The deal was independently reported by Brandon Capital, the Medical Research Commercialisation Fund and multiple New Zealand and Australian outlets.
University deputy vice-chancellor Harlene Hayne characterised commercialisation as 'early days' for Otago in 2009, noting biomedical innovations typically take five to twenty years to reach market and citing Stanford's enterprise arm taking fifteen years to break even — a useful caution against judging young university TTOs on short time horizons.

Read the full analysis: https://otagoinnovation.com/